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Transfusion-transmitted hepatitis B virus infectionq
Daniel Candotti1,*, Jean-Pierre Allain2
1National Health Service Blood & Transplant, Cambridge Blood Centre, Long Road, Cambridge CB2 2PT, UK
2Department of Haematology, University of Cambridge, Cambridge, UKHepatitis B virus (HBV) remains a major risk of transfusion-transmitted infection due to the pre-seroconversion window
period (WP), infection with immunovariant viruses, and with occult carriage of HBV infection (OBI). Reduction of HBV
residual risk depends upon developing more sensitive HBV surface antigen (HBsAg) tests, adopting anti-HBc screening
when appropriate, and implementing HBV nucleic acid testing (NAT), either in minipools or more eﬃciently in individual
samples. HBV NAT combines the ability to signiﬁcantly reduce the window period and to detect occult HBV carriage sub-
stantiating decades of clinical observation that HBsAg-negative /anti-HBc-positive blood could transmit HBV. Clinical
observations suggest limited transmission rate of occult HBV compared to WP. Low transmission rate might be related
to low viral load observed in OBIs or to the presence of mutants associated with occult carriage. OBIs carrying detectable
anti-HBs (50%) are essentially not infectious by transfusion. However, recent data suggest that the neutralizing capacity
of low anti-HBs may be ineﬃcient when overcome by exposure to high viral load. Anti-HBc blood units without detectable
anti-HBs appear moderately infectious except in immunocompromised recipients. Immunodeﬁcient elderly and patients
receiving immunosuppressive treatments may be susceptible to infection with lower infectious dose even in the presence
of anti-HBs. The immune status of blood recipients should be taken into consideration when investigating ‘‘post-transfu-
sion” HBV infection. Pre-transfusion testing and post-transfusion long-term follow-up of recipients, and molecular anal-
ysis of the virus infecting both donor and recipient are critical to deﬁnitively incriminate transfusion in the transmission of
HBV.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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RBC, red blood cells; PC, platelet concentrates.HBsAg prevalence) including Sub-Saharan Africa, South
East Asia, China and the Amazon Basin, transmission
occurs essentially vertically or horizontally at young ages,
and 70–90% of the adult population has serologic
evidence of prior infection (anti-HBc). Countries from
the Mediterranean area, Eastern Europe and the Middle
East with intermediate endemicity (2–7% HBsAg) have
a mix of vertical, horizontal, health-care-related (i.e.
blood transfusion), unsafe injections, and sexual routes
of transmission. In areas of low endemicity (<2%HBsAg)
including Western and Northern Europe, North
America, part of SouthAmerica, andAustralia, transmis-
sion occurs mainly among young adults through sexual
contacts or unsafe injections [1].
Before 1970, approximately 6% of multi-transfused
recipients acquired transfusion-transmitted HBV. OverPublished by Elsevier B.V. All rights reserved.
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hepatitis B virus has been steadily reduced, yet HBV
transmission remains the most frequent transfusion-
transmitted viral infection. The residual risk of HBV
transfusion transmission is mainly related to blood
donations negative for HBsAg that have been collected
either during the pre-seroconversion ‘window period’
(WP) deﬁned as the time between infection and detec-
tion of a viral antigen or antibody marker, or during
the late stages of infection. Implementation of HBV
DNA screening has the potential to signiﬁcantly reduce
the WP and to reveal ‘occult’ HBV infection or carriage
(OBI) [2]. OBI is deﬁned as the presence of HBV DNA
without detectable HBsAg outside the WP. It is gener-
ally admitted that pre-seroconversion WP infections
are most likely to transmit HBV but transmission from
occult HBV infection remains debated [3].
The aim of the present review is to examine the resid-
ual risk of transfusion-associated HBV transmission
according to HBV screening strategies of blood dona-
tions, and the infectivity of HBV-containing blood
products according to the immune status of recipients.2. Detection of HBV in blood donors
2.1. Improvements and limitations of HBsAg testing
HBsAg tests remain the ﬁrst-line of blood screening
for HBV. Current HBsAg screening assays are enzyme
immunoassays (EIAs), including enzyme-linked immu-
nosorbent assays (ELISAs), and chemiluminescence
immunoassays (CLIAs). These diﬀerent assays have sen-
sitivity ranging between <0.1 and 0.62 ng of HBsAg per
mL (1 ng/ml corresponds to approximately 2 IU/mL)
[4,5]. A chemiluminescent enzyme immunoassay
(CLEIA) prototype has been developed that claims a
sensitivity of 0.22 mIU/mL and the ability to reduce
the WP by 17 days compared to the CLIA systems
in use [6].
Due to high cost and considerable equipment require-
ments, these HBsAg assays may not be aﬀordable for
small-scale blood services particularly in resource-lim-
ited developing countries. Rapid immunochromato-
graphic HBsAg tests have been developed and were
evaluated in high prevalence areas [7–9]. Comparative
studies showed that rapid tests are less sensitive than
most EIAs [7,8,10].
Diﬀerences in analytical sensitivity and speciﬁcity in
detection of HBsAg from viruses of diﬀerent genotypes
have been reported among commonly used EIAs
[11,12]. Mutations associated with conformational and
hydrophobic changes within and outside the immuno-
genic major hydrophilic region (MHR) of the S antigen
(the main target for capture antibodies used in diagnos-
tic tests) and with reduced synthesis or secretion ofHBsAg may account solely or in conjunction for the
failure or a signiﬁcant decrease in detecting HBsAg by
immunoassays [13]. Mutations may occur naturally
from escaping active or passive immunity or antiviral
therapy. Occurrence of such mutant strains may reach
30% in areas of high endemicity following vaccination
programs [14,15]. Another cause of failure in detecting
HBsAg may be the concomitant presence of hepatitis
B surface antibodies (anti-HBs) leading to the formation
of circulating immune complexes not or poorly dis-
placed by HBsAg capture antibodies [16,17].
HBsAg-positive/HBV DNA-negative samples are
found in 2–16% of blood donor carriers [10,18,19]. Docu-
mented cases of donors conﬁrmed HBsAg-positive a few
days after HBV vaccination were reported as a cause of
unnecessary deferral of blood donors [20,21]. As a result
blood donation within a month from receiving HBV vac-
cination is discouraged.
2.2. Anti-HBc testing
Anti-HBc screening for blood donation was initially
introduced in the mid 1980s as a surrogate marker for
non-A, non-B hepatitis. The 40% eﬃcacy was made
totally redundant with the implementation of speciﬁc
antibodies to hepatitis C virus. After being argued as
useful to blood safety as a ‘‘lifestyle” marker targeting
homosexual men and intravenous drug abusers, it was
maintained where implemented as improving HBV
safety.
Several studies conducted in Europe and in North
America showed that approximately 90% of blood
donors carrying anti-HBc also carried anti-HBs signal-
ling recovered HBV infection with a frequency of
approximately 90% [10]. The remaining 10% carried
either false-positive anti-HBc in a relatively high propor-
tion due to poor assay speciﬁcity or true anti-HBc
[22,23]. These samples called ‘‘anti-HBc only” may orig-
inate either from recovered infections having lost detect-
able anti-HBs or from late stage chronic infections
having lost detectable HBsAg. Evidence of a secondary
anti-HBs response after a single dose of HBV vaccine
indicated that a large proportion of anti-HBc-only
donors had indeed recovered from the infection indi-
cated by activable memory B cells [24,25]. The issue
was further complicated by detecting low levels of
HBV DNA not only in anti-HBc only donations but
also in some units carrying low-level anti-HBs.
In donor populations with low prevalence of anti-
HBc, deferring all reactive donors was considered
aﬀordable in terms of donation loss and more econom-
ical than introducing anti-HBs testing to diﬀerentiate
between presumably non-infectious (anti-HBs
P100 IU/L) and potentially infectious donations (no
anti-HBs or anti-HBs <100 IU/L). This strategy was
not defendable in areas of higher prevalence where
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blood supply too severely and at a non-aﬀordable cost.
The strategies left open to these areas were either a sero-
logic testing algorithm with anti-HBc followed by anti-
HBs or implementation of highly sensitive HBV DNA
screening. The latter was adopted in aﬄuent countries
in Mediterranean Europe and Poland as well as in Sin-
gapore, Hong Kong, Taiwan and Thailand in Eastern
Asia or in South Africa [19,26–30]. In less aﬄuent areas,
the debate remains open.
2.3. HBV nucleic acid testing (NAT)
In the past ﬁve years, HBV DNA detection assays
that combined simultaneous detection of human immu-
nodeﬁciency virus RNA, hepatitis C virus RNA, and
HBV DNA (‘‘multiplex” NAT assays) and correspond-
ing automated testing platforms have made HBV NAT
blood screening feasible. Commercial assays based on
PCR (Cobas TaqScreen multiplex test; Roche Molecu-
lar System) and on TMA (Procleix UltrioTM Assay;
Novartis/Chiron Blood Testing) showed speciﬁcity of
99.9% and 99.8%, and sensitivity of 8 IU/mL
(40 geq/mL) and 12 IU/mL (60 geq/mL), respec-
tively [4,28]. Such high sensitivity allows HBV NAT to
signiﬁcantly reduce the WP left by the most sensitive
HBsAg tests. However, the ability of NAT to reduce
the WP depends not only on the sensitivity of both the
molecular and serological tests, but also on the sample
volume (200 or 500 ll) as well as the dilution factor
introduced by pooling samples [4,31–34]. Comparing
seven HBsAg assays and seven NAT assays (three indi-
vidual donor [ID] NAT and four minipool [MP] of 16 or
24 donors NAT tests) on acute-phase seroconversion
panels, Biswas and colleagues showed that MP NAT
and ID NAT reduced the HBV WP by 9–11 days and
25–36 days, respectively, compared to currently licensed
HBsAg tests [4]. This leaves a WP of 40–50 days and 15–
34 days with MP and ID HBV NAT, respectively.
Beyond shortening the WP, NAT screening, particu-
larly in individual units, has uncovered a relatively large
number of HBsAg-negative ‘‘occult” HBV infection or
carriage [2,3]. On the basis of the HBV antibody proﬁle,
OBI may be stratiﬁed into seropositive OBI (anti-HBc
and/or anti-HBs positive) and seronegative OBI (anti-
HBc and anti-HBs-negative) [35]. Potential biological
explanations for seropositive OBI include the chronic
carrier state in which HBsAg has declined over years
to a sub-detectable level. OBIs are mainly found in older
donors, nearly 100% carry anti-HBc, and approximately
50% also carry anti-HBs suggesting that OBIs occur lar-
gely in individuals having recovered from the infection
but unable to develop a totally eﬀective immune control
[36]. Finally, mutations in the HBV genome aﬀecting
viral replication, S antigen production or detection
may account for OBI [13,37,38].Seronegative or primary OBIs might have either
progressively lost HBV-speciﬁc antibodies or are anti-
body-negative from the beginning of the infection. In
the absence of systematic DNA screening and follow-
up investigations in seronegative individuals, very
limited data support primary occult carriage and the
true frequency of this condition remains unknown.
One case was identiﬁed in a look-back study for post-
transfusion hepatitis B [39]. Recently, Manzini and
colleagues reported a blood donor who tested HBV
NAT positive but did not develop detectable HBsAg
over a period of 97 days despite anti-HBc and anti-
HBs seroconversion [40]. Three cases of OBI in the acute
stage have been reported from the Japanese Red Cross
but viral loads were >104 copies/mL (J 103 IU/mL)
and S escape mutants could not be ruled out in one of
the donors [41].
OBIs are usually characterized by very low HBV
DNA load in plasma (<200 IU/mL). Consequently,
the occurrence of viremia that is near the assay detection
limit and the potential for ﬂuctuating HBV viremia in
chronically infected persons suggest that some donors
with ongoing HBV infection would not be detected
using highly sensitive NAT in very small pools
(<10 plasmas) or even in individual units [4,26,31,40,
42,43]. This was demonstrated in Japan when NAT
was negative in pools of 50 plasmas but positive in pools
of 20 [44]. The apparently marginal beneﬁt of MP NAT,
the high cost of ID NAT testing and its very low quality-
adjusted-life-year beneﬁt estimate have raised questions
about the cost-eﬀectiveness of HBV NAT implementa-
tion in low prevalence countries [43,45]. These argu-
ments do not apply in countries with higher HBV
prevalence [8,46]. It is unlikely that HBV NAT will
replace current serological testing studies since up to
15% of HBsAg-conﬁrmed-positive anti-HBc-positive
donations test negative for HBV DNA even by ID-
NAT [10,19,47].
2.4. Additional developments to potentially reduce HBV
transfusion transmission
Viral inactivation methods and large-scale HBV vac-
cination programs have the potential to reduce HBV
transfusion transmission. Viral inactivation technologies
are applied to plasma and platelet concentrates but still
need development to be applied to red cell components
or whole blood. A decrease of HBV infection incidence
was observed following HBV vaccine implementation in
many countries with moderate/high HBV endemicity
[48–50]. However, it may take many years to decrease
HBV prevalence among blood donors as the vaccine is
usually given to newborns, but also in some programs
to adolescents and at-risk health-care workers. Pereira
and colleagues reported the disappearance of HBV
DNA in the serum of patients with OBI after immuniza-
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response could not be ascertained [51]. Vaccination
however may favour the development of escape
mutants. Anti-HBs in vaccinated people become unde-
tectable over time and they are susceptible to HBV
infection, and up to 5% of vaccinated individuals do
not respond [52].3. Estimation of HBV residual transfusion transmission
risk
The risk of transfusion-transmitted infections has
been widely estimated by using the incidence-window
period model [53]. This model estimates the risk by mul-
tiplying the incidence of new infection by the average
time interval during which a newly infected donor is
capable of transmitting the infection [54]. However,
the length of the WP varies considerably depending on
the screening strategy as discussed above, and whether
all WP donations are considered infectious or whether
the ‘‘eclipse” phase preceding the ramp-up phase is con-
sidered infectious. Recently, Busch and colleagues pro-
posed a modiﬁed residual risk model using an
infectious WP of 38.3 days derived from a HBV dou-
bling time of 2.6 days and assuming that one infused
HBV copy will cause infection [55]. The second critical
parameter is the incidence of infection that is directly
measured as the number of newly infected (seroconvert-
ing) donors divided by the observed person-years at risk.
This applies only to repeat donors who made more than
one donation during the study period, and it may under-
estimate the risk as ﬁrst time donors might be at greater
risk of infection than repeat donors [56]. The most
common approach is to measure seroconversion toTable 1
Estimated residual risk of transfusion-transmitted HBV infection (per million
Country HBV endemicity HBV RR withou
England Low 1.66
Belgium Low 5.0
France Low 0.69
The Netherlands Low 2.1
Finland Low 2.04
Germany Low 4.35
Switzerland Low 8.69
Canada Low 6.55
USA Low 2.05–4.88
Australia Low 0.75
Greece Moderate 7.5
Italy Moderate 13.9–15. 8
Spain Moderate 9.78
China High 30.6–57.1
Hong Kong High 200
a Anti-HBc screening in ﬁrst-time blood donors.
b Limited anti-HBc screening on a voluntary basis.
c Anti-HBc screening implemented in 2005.
d Anti-HBc screening in donors with a history of hepatitis.HBsAg despite the rapid disappearance of this marker
in a few months after infection in 95% of immunocom-
petent adults [41]. Therefore, a newly infected donor
would not be identiﬁed as such if HBsAg is cleared from
the blood between donations and true HBV infection
incidence will be underestimated. To resolve this issue,
an adjustment factor was calculated [57]. Diﬀerent
adjustment factors apply to diﬀerent donor populations,
and prevalence might not accurately reﬂect the incidence
of transfusion-transmissible viral infection. Other inﬂu-
encing factors such as test or process errors, mutant
viruses that are not detected by blood donation screen-
ing, and OBI are not considered in the model [58].
Residual risk estimates reported from diﬀerent countries
are summarized in Table 1. Data comparison should be
undertaken with caution since some of the listed coun-
tries perform anti-HBc testing in the whole donor pop-
ulation or in particular subsets of donors. In countries
not performing anti-HBc testing, seropositive-OBI
donors represent a substantial increment in the transfu-
sion transmission risk. Despite all these limitations, the
residual risk estimates provided seem to have some
validity as they tend to parallel the rates of HBV ende-
micity. The residual risk per million donations is 0.69–
8.69, 7.5–15.8, and 30.6–200 in areas of low, moderate,
and high endemicity, respectively (Table 1).
The incidence of anti-HBc seroconversion has been
proposed as a modiﬁer of the WP-based model resulting
in a reduction of risk from 0.69 to 0.49 [60]. This adjust-
ment appears legitimate but its reliability highly depends
on the criteria used to identify anti-HBc seroconversion
[70]. Measuring the incidence of anti-HBc seroconver-
sion may overestimate the HBV infection incidence
related to the poor speciﬁcity of anti-HBc assays and
the lack of conﬁrmatory assays [71]. Laperche anddonations from repeat donors).
t HBV NAT Anti-HBc screening References
No [59]
Yes/noa [53]
Yes [60]
No [53]
No [53]
Yes/nob [61]
No [62]
Yesc [63]
Yes [64,65]
Yes/nod [66]
No [53]
No [53,67]
No [68]
No [69]
No [53]
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the concomitant detection of anti-HBe, anti-HBs in
the absence of vaccination, and HBV DNA when imple-
mented. Recent data obtained in European blood
donors indicates that HBV DNA-positive/anti-HBc-
positive without anti-HBe is as or more frequent than
associated with anti-HBe [26,71–73].
Another method proposes to calculate the incident
infection rate as the number of NAT-yield donations
divided by the number of person-years [54,55,63]. This
method allows the determination of the incidence rate
in all donations, and occult HBV carriage will be
included in the calculation of the residual risk. This
method highly depends on the accuracy of the estima-
tion of HBV NAT yield. Indeed, HBV DNA yield
appears directly related not only to the analytical sensi-
tivity and pool size of the HBV NAT assay, but also to
the analytical sensitivity of the HBsAg used for screen-
ing and to the general HBV prevalence in the donor
population. HBV NAT yields reported from countries
with low, moderate, and high HBsAg prevalence range
between 1:4000 and 1:730,000 [22,65,72,74–77], 1:4000
and 1:20,300 [26,27,78–80], and 1:192 and 1:5200
[8,10,19,28–30,81], respectively. As studies conducted
in diﬀerent countries used diﬀerent serological and
NAT assays with variable pool sizes, and were per-
formed in selected (repeat, ﬁrst time, or anti-HBc-posi-
tive donors) or unselected populations of blood
donors, comparison of results is diﬃcult. Despite these
limitations, HBV DNA yield increases with HBsAg
and anti-HBc prevalence, irrespective of MP- or
ID-NAT screening or anti-HBc status [82,83]. In low-
prevalence Germany, implementation of HBV NAT
(essentially in-house assay) in pool of 96 submitted to
prolonged high-speed centrifugation or individual unit
resulted in residual risks of 1.61 and 1.23 per million
donations, respectively, compared to 4.35 per million
without NAT [61]. Similarly, a study conducted in
high-prevalence China showed that a residual risk of
30.6 per million donations after HBsAg screening was
reduced to 29.0 and 17.4 when NAT was used in pools
of 16 and in individual testing, respectively [69].4. HBV transmission by transfusion
4.1. Determining the HBV infectious dose(s)
The estimated residual risk of HBV transfusion trans-
mission remains signiﬁcantly higher than the risk of
either HIV-1 or HCV. Whether residual risk estimates
translate into true rate of infection is largely unknown
since estimates are generally based on the simpliﬁcation
that all HBV DNA-containing donations are infectious.
Studies have attempted to address this question by
using the chimpanzee model. Genotype A or genotypeC inoculum derived from two infected blood donors
who were in the pre-acute phase (HBsAg and HBV
DNA-positive but anti-HBc-negative) were used to
infect two chimpanzees whose pre-acute phase serum
samples were then used to infect two other chimpanzees.
The estimated minimum HBV copy numbers that could
infect 50% of the chimpanzees (CID50) was approxi-
mately 10 copies or geq, irrespective of HBV genotype
[84]. A similar result was reported from three chimpan-
zees infected with serum from a HBV genotype A-
infected individual in the acute phase of infection [44].
Using three serum inoculae from chronic carriers
(HBsAg-positive and anti-HBc-positive), Hsia and col-
leagues estimated CID50 was 169 geq for genotype A,
3 for genotype C, and 78 for genotype D [85]. Utilizing
a chimeric mouse model tolerating human liver tissue,
Japanese investigators determined the HBV infectious
dose of a pre-acute and late acute HBV serum required
for transmission to be 10 and 100 geq, respectively [86,87].
In humans, HBV transmission was reported from
donors in the WP and OBI donors showing HBV
DNA load <20 IU/mL (Table 2) [42,88,89]. However,
in some cases, units from WP and OBI donors were
not infectious even though viral load ranging between
<20 and >500 IU/mL (<100 and >2500 geq/ml) was
transfused [31,88–90]. The lack of clear relationship
between infectivity and viral load in blood components
may be related to immune factors aﬀecting the suscepti-
bility to infection in recipients as discussed below. In
addition, HBV infectivity is essentially related to the
amount of plasma transfused and the viral load in the
product. At equal volume of product, fresh-frozen
plasma (FFP) and platelet concentrates (PC) suspended
in plasma were 3- to 20-fold more infectious than red
cell concentrates containing approximately 20% of
plasma.
4.2. Risk of transmission from clinical data
While HBV transmission from HBsAg-negative
donations is supported by several studies since the early
1980s [91], it is not a frequently reported event, at least
in low-prevalence countries, consistent with the small
number of WP and occult carriage reported. In the Uni-
ted States, the risk of transfusing a potentially infectious
HBsAg-negative/anti-HBc-positive/HBV DNA-positive
unit has been reported to be 1 in 50,000 donations if
all HBV-positive donations were assumed to be infec-
tious [23,65]. However, of 7381 cases of acute hepatitis
B reported in 2003, 49 were initially reported as transfu-
sion-associated. Only 10 of those were further conﬁrmed
by the Centers for Disease Control and Prevention as
acute cases of hepatitis B involving transfused blood
products and ﬁnally only 1 case could be associated with
a single infected donor [92]. Similar data were reported
from Canada, the UK, and Japan [75,89,93].
Table 2
Transfusion transmission of HBV from HBsAg-negative blood donations.a
Reference Donors Products
transfusedc
Transmission cases Recipients
anti-HBs (IU/L)Anti-HBc HBV DNA
(IU/mL)
Anti-HBs
(IU/L)b
HBV
status
Nb recipients Nb transmission
[94] Neg. Weak pos. WP PC 1 1 NAe
RBC 1 1 NA
FFP 1 1 NA
[31] Neg. 660 WP Plasma 1 1 NA
RBC 1 0 NA
Neg. Neg. WP PC 1 1 NA
Neg. 600 WP PC 1 1 NA
Neg. 160 WP Plasma 1 1 NA
Neg. >10 WP NA 1 1 NA
Neg. >10 WP NA 1 1 NA
Neg. >10 WP NA 1 1 NA
Pos. >10 NA OBI NA 1 1 NA
Pos. >10 NA OBI NA 1 1 NA
[42] Neg. <25 WP RBC 1 1 NA
PC 1 1 NA
[93] Neg. Pos. WP 1 1 NA
Neg. Pos. WP 1 1 NA
Neg. Pos. WP 1 1 NA
Neg. Neg. WP 1 NA
[90] Pos. 10–100 Neg. OBI NA 11 2 NA
[95] Pos. <10–260 Pos. OBI RBC 9 0 NA
(2 534–7 371) FFP 2 0 NA
[88] Weak <10–40 Neg. OBI PC 10 6 NA
Pos. NA
[96] Pos. <10 Pos. OBId PC 65 0 NA
[89] 1 Pos. <20 Neg. OBI FFP 1 1 NA
32 Pos. <20–24 11 Pos OBI 17 RBC 32 0 NA
12 Neg. 14 FFP, 1 NA
9 Und. PC NA
11Neg. <20–76 WP 5 RBC, 4 11 11 NA
FFP, 2 PC NA
11Neg. <20–60 WP 5 RBC, 4 11 0 NA
FFP, 2 PC NA
[97] Pos. 180 Pos. (12) OBI FFP 1 1 Neg.
RBC 1 1 Neg.
<1–63 Pos. NA 2 0 Neg.
(15–29)
[98] Neg. >500 WP RBC 1 1 Pos.
PC 1 0 (12–65)
Pos.
(15)
[99] Neg. 171 WP PC 1 1 Neg.
1 0 Pos. (135)
1252 1 1 Neg.
1 0 Pos. (164)
a Only conﬁrmed HBV transfusion-associated transmission were considered.
b 1 International Unit (IU) is equivalent to approximately 5 genome equivalents (geq) or copies for HBV genotype A, subtype adw2.
c RBC, red blood cells; FFP, fresh-frozen plasmas; PC, platelet concentrates.
d Breakthrough of an escape mutant.
e NA, not available.
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anti-HBs-positive and negative OBI units can transmit
HBV; (2) the conﬁrmed HBV transmission rate ofWP-derived donations is higher than by occult carriers
(81% versus 19%) but may be biased by the large num-
ber of Japanese cases identiﬁed with a peculiar set of
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transmission can be associated with extremely low level
of HBV DNA in anti-HBc-positive-only units (<20 IU/
mL) or blood collected during the very early phase of
acute infection (eclipse phase) in which neither HBsAg
nor HBV DNA is detectable [31,93]; (4) HBV DNA load
is similar in infectious and non-infectious anti-HBc-
positive donations, suggesting that viral load is not the
only factor for infectivity; and (5) the presence of anti-
HBs seems to largely protect from transmission
[89,100], except in rare cases [97] (Fig. 1).
The concomitant presence of anti-HBs with HBV
virions in the peripheral blood of donors neutralizes in
proportion of antibody titer and ability to recognize sur-
face protein antigens. Experiments in chimpanzees
showed no HBV infection in animals transfused with
blood from three anti-HBs-positive human plasmas,
despite exposure to an HBV DNA dose known to be
infectious in the absence of anti-HBs [101]. The presence
of anti-HBs following natural infection, vaccination, or
passive immunoprophylaxis prevents de novo HBV
infection in transplanted patients receiving anti-HBc-
positive livers [102–105]. Consequently, the transfusion
of anti-HBc-positive blood with high levels of anti-
HBs (>200 IU/L) is allowed in Japan and no post-trans-
fusion cases have been documented from such units
[31,32,89]. Dreier and colleagues reported intermittent
low HBV DNA levels (<10–260 IU/mL) over a 7-year
period in an HBsAg-negative anti-HBc-positive donor
with anti-HBs (>2000 IU/L) but no HBV transmission
occurred [95]. Another study described a breakthrough
HBV escape variant in a plateletpheresis donor [96].
Infection occurred three years after vaccination, the
donor developed a persistent low-level HBV-infection
(HBsAg-negative, anti-HBc-positive, HBV DNA at lev-
els <5 IU/mL) despite a high vaccine-induced anti-HBs
response (>1000 IU/L). Lookback of 65 recipients of
PC from this donor (200 IU/donation) did not reveal
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Fig. 1. Relationship between HBV DNA load and anti-HBs reactivity in
an OBI donor associated with transfusion transmission of HBV (modiﬁed
from [97]). Open and plain circles indicate anti-HBs reactivity (IU/L)
and HBV DNA load (IU/mL), respectively. The dashed line indicates
absence of HBV DNA testing. HBV transmission is indicated by black
vertical arrows; absence of transmission by an open arrow.The principle of protection by units with high levels
of anti-HBs is commonly accepted, although there is
no agreement on the threshold level but 100 IU/L is
often cited [106]. No evidence of transmission was found
in 131 recipients who were transfused with 97 compo-
nents containing anti-HBc and anti-HBs at levels
<100 IU/L [107]. In contrast, others described ﬁve cases
of HBV transmission presumably linked to anti-HBc-
positive donors: three lacked anti-HBs and two had
low level of anti-HBs (probably <10 IU/L) [23,108].
Recently, one case of an OBI donor with anti-HBs
who transmitted to two immunocompetent transfusion
recipients of FFP and red blood cells (RBC) was
reported [97]. The implicated donation contained anti-
HBc, anti-HBs (12 IU/L), and 180 IU/mL of HBV
DNA. Previous donations contained 6–10 times less
viral DNA than the index donation, anti-HBs levels ran-
ged between 15 and 29 IU/L, and no clinical evidence of
HBV transmission was recorded in 14 recipients. It was
speculated that the main factor for infectivity was a tem-
porary higher viral load suﬃcient to overcome the rela-
tively weak neutralizing capacity of a low anti-HBs
level. This interpretation was supported by a secondary
anti-HBs immune response. This particular case clearly
illustrates that the neutralizing capacity of low-level
anti-HBs is limited and reinforces the validity of consid-
ering anti-HBs below 50–100 IU/L to be poorly protec-
tive from infectivity when HBV DNA is present. This
factor needs to be considered in triggers to maintain
eﬀective post-vaccination protection [50,109–112].
The immune status of the recipient is another critical
factor in transfusion transmission of HBV. After acute
HBV infection was diagnosed in a regular apheresis
donor, four platelet components recipients were identi-
ﬁed; two HBV-naı¨ve were infected but two who were
anti-HBs-positive pre-transfusion (135 and 164 IU/L)
were not. Several studies indicated that recipients of
anti-HBc-positive organs (e.g. liver) developed HBV
infection, even if HBV DNA was not detected in the
donors’ serum [113–116]. These data suggest an
increased susceptibility to HBV infection of transplant
patients undergoing intensive immunosuppressive ther-
apy in the absence of prophylactic treatment. This situ-
ation can be probably derived from organs to blood
components as approximately 50% of recipients of
blood components in Western Europe present some
degree of immunodeﬁciency [117]. It was shown that
both active and passive neutralizing anti-HBs likely
delayed but did not prevent acute infection when the
immune system was impaired [98].
4.3. Diagnosis of transfusion-transmitted HBV
Transfusion transmission can be documented by (1)
notifying and testing donors that have been implicated
in a case of possible post-transfusion hepatitis B
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administration of potentially infectious HBV-containing
blood products (lookback); and (3) prospective testing
of donor–recipient pairs. Each strategy has its own lim-
itations. No prospective studies have been conducted so
far because it requires an extremely large number of
patients and high cost.
The traceback strategy relies primarily on clinical evi-
dence and proper diagnostic of hepatitis B in the recipi-
ent. Inaba and colleagues reported three of four cases of
acute hepatitis B and two suspected seroconversions
that were not recognized by local physicians as being
related to transfusion [88]. Twenty UK cases of hepatitis
B associated with presumably infectious donors were
identiﬁed (but only four were conﬁrmed) over the past
15 years, none of which were suspected by local physi-
cians in a timely fashion [93]. Clinical data suggest that
only 20–35% of recipients will be symptomatic, and the
length of the incubation period before symptoms
develop can extend up to 6 months, irrespective of the
amount of virus transfused [3,31]. HBV incubation time
can be considerably prolonged (up to 13 months) in
unusual circumstances involving an impaired immune
system and active or passive neutralizing antibodies to
HBV in the recipient [98,100]. There is preliminary evi-
dence that immunocompromised patients are not only
more susceptible to lower infectious dose including in
the presence of anti-HBs but also at higher risk of devel-
oping chronic infection [105]. The 50% mortality rate
within 6–12 months post-transfusion reported in trans-
fusion recipients may also limit identiﬁcation of HBV
transmission [118].
Lookback of recipients who were transfused with
donations from a newly identiﬁed HBV-infected repeat
donor is often used to identify recipients at risk of
HBV transfusion transmission [118]. Evidence of trans-
fusion transmission of HBV may not be obtained
because pre-transfusion samples are rarely available,
HBV infections might have resolved before they are
identiﬁed by lookback, and often recipients cannot be
traced or samples obtained [63]. As HBV marker levels
may ﬂuctuate over time [47,88], follow-up of suspected
donors and testing of archived samples are necessary
to exclude recent infection and false-positive
[106,107,119]. Testing for archived donations and recipi-
ent samples requires access to a frozen repository of
donor/recipient samples. Such system exists in several
national blood services [31,89,120].
Post-transfusion hepatitis B is not necessarily transfu-
sion-transmitted and iatrogenic sources of infection
should be systematically investigated before concluding
that HBV-infected blood donors are involved in viral
transmission [109,121,122]. In a systematic investigation
of suspected transfusion-transmitted HBV infections,
Matsumoto and colleagues showed that the majority
of reported cases could not be linked to laboratorytesting of transfused blood [31]. Caution should be exer-
cised in concluding that a suspected transfusion-trans-
mitted case is causally related to transfusion, unless
other iatrogenic sources of infection have been elimi-
nated, adequate donor follow-up and laboratory testing
have been performed, and more importantly, pre- and
post-transfusion testing of recipients has been com-
pleted. Unfortunately, pre-transfusion testing of the
recipient is missing in many studies making diﬃcult to
establish if the investigated recipient was infected before
or after transfusion [63,100,109]. In addition, HBV reac-
tivation has been largely documented in immunocom-
promised individuals with past history of hepatitis [123
for review]. Dependent on the degree of T-cell depletion,
the risk of reactivation varies, low as demonstrated in
kidney transplant recipients, or high in liver transplant
recipients or patients treated for graft-versus-host dis-
ease or undergoing allogeneic bone marrow or stem cell
transplantation or treatment with aggressive chemother-
apy or monoclonal antibodies against T- or B-cells. In
the latter groups, close monitoring of HBV DNA for
anti-HBc-positive recipients or systematic treatment
with antiviral drugs (i.e. lamivudine) have been advo-
cated [123]. Deﬁnitive evidence of transfusion transmis-
sion can be obtained by genomic analysis of the viral
strains present in both donor and recipient.5. Conclusions
Despite continuous technical improvement in blood
donation screening, hepatitis B infection remains a
major risk of transfusion-transmitted viral infection.
The residual risk of HBV transmission is related to the
pre-seroconversion window period, infection with
immunovariant viruses, and with occult carriage of
HBV. Reduction of HBV residual risk is achieved by
developing more sensitive HBsAg tests, by adopting
anti-HBc screening if appropriate, and recently by
implementing HBV nucleic acid testing, either in mini-
pools or more eﬃciently in individual samples. Com-
pared to serological testing, HBV NAT combines the
ability to signiﬁcantly reduce the window period and
to detect occult HBV carriage. HBV NAT yield in
HBsAg-negative blood donations was studied in low-,
moderate-, and high-endemic areas in pools and individ-
ual plasmas. Anti-HBc screening has the potential of
excluding the majority of OBIs, leaving only the rare
cases of primary OBI or of escape mutant associated
with anti-HBs alone. However, it does not detect pre-
seroconversion window period infections, and is not
practical in areas with anti-HBc prevalence >5% where
too many donor deferrals would negatively impact the
blood supply. Based on available data, NAT is the only
theoretical choice to reduce HBV risk in high-endemic
countries. However, most of these countries do not have
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tives to simplify methods and to reduce NAT cost
should be investigated.
The development of HBV NAT assays substantiated
decades of clinical observation that HBsAg-negative/
anti-HBc-positive blood could transmit HBV. For the
transfusion community, the remaining critical question
is: are blood components from OBI donations infectious
by transfusion? Clinical observations suggest limited
transmission rate compared to WP yield cases. Low
transmission rate may be related to the low viral loads
generally observed in OBIs (even if the HBV infectious
dose by transfusion is still unknown) or to the presence
of defective variants associated with occult carriage.
OBIs carrying detectable anti-HBs (50%) are essen-
tially not infectious by transfusion. However, recent data
suggest that the neutralizing capacity of low anti-HBs
may be ineﬃcient when overcome by exposure to high
viral load. Anti-HBc blood units without detectable
anti-HBs appear moderately infectious except in immu-
nocompromised recipients. Immunodeﬁcient elderly and
patients receiving immunosuppressive treatments (organ
transplantation or cancer chemotherapy) may be suscep-
tible to infection with lower infectious dose even in the
presence of anti-HBs. The immune status of blood recip-
ients should be taken into consideration when investigat-
ing ‘‘post-transfusion” HBV infection. Pre-transfusion
testing and post-transfusion long-term follow-up of
recipients, and molecular analysis of the virus infecting
both donor and recipient appear essential to deﬁnitively
conﬁrm transfusion transmission of HBV.
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